Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases.

Richter Jg¹, A Beichert², T Filla², G Chehab², D Sert³, M Aslandag³, Jhw Distler², M Schneider², I Frohne⁴

¹Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany.; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany.. Electronic address: jutta.richter@med.uni-duesseldorf.de.

²Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany.; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany.

³Asepha Käthe-Kollwitz-Straße 60 04109, Leipzig , Germany.

⁴Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany.; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany.; Private practice for rheumatology, Essen, Germany.

PubMed DOI

Abstract

BACKGROUND: Though medical cannabis (MC) may have a role in the treatment of pain and anti-inflammation in patients with inflammatory rheumatic diseases (IRD), evidence and data are rare. We evaluated IRD patients' attitudes towards the setting of a clinical trial (CT) with MC as prerequisites for the design of a prospective study in phytopharmacological translational research. MATERIAL AND METHO…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.